EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cleveland BioLabs's enterprise value is $57.63 Mil.
Cleveland BioLabs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2021 was $-2.66 Mil. Therefore, Cleveland BioLabs's EV-to-EBITDA for today is -21.63.
The historical rank and industry rank for Cleveland BioLabs's EV-to-EBITDA or its related term are showing as below:
CBLI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -109.84 Med: -3.35 Max: 99.11
Current: -25.35
During the past 13 years, the highest EV-to-EBITDA of Cleveland BioLabs was 99.11. The lowest was -109.84. And the median was -3.35.
CBLI's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.22
vs CBLI: -25.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Cleveland BioLabs EV-to-EBITDA Historical Data
The historical data trend for Cleveland BioLabs's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cleveland BioLabs's EV-to-EBITDA
For the Biotechnology subindustry, Cleveland BioLabs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cleveland BioLabs's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cleveland BioLabs's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cleveland BioLabs's EV-to-EBITDA falls into.
Cleveland BioLabs's current Enterprise Value is $57.63 Mil.
Cleveland BioLabs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cleveland BioLabs's PE Ratio for today is calculated as:
Cleveland BioLabs's share price for today is $4.35.
Cleveland BioLabs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.180.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Cleveland BioLabs's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Cleveland BioLabs (Cleveland BioLabs) Business Description
Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for the prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CBLI has been successfully added to your 